Combined Forces Drive BTTC

The Brain Tumor Trials Collaborative (BTTC) was created in 2003 - a combined effort of many professionals, entities and organizations to help those suffering from brain tumors. The National Cancer Institute's (NCI) Center for Cancer Research serves as the lead institution and provides the administrative infrastructure, clinical database and oversight for the collaborative.

Several additional brain cancer-focused medical centers have since joined the BTTC. These institutions allow patients across a broad geographic range to participate in cutting-edge clinical trials and more rapidly determine the benefits of various therapies.

The mission of the BTTC is to develop and perform state-of-the-art clinical trials in a collaborative and collegial environment, advancing treatments for patients with brain tumors, merging good scientific method with concern for patient well-being and outcome.

Goals of the BTTC

  • Provide patients access to innovative treatments through the BTTC Clinical Trials Network.
  • Accelerate the pace of translating laboratory findings into hypothesis-based clinical trials.
  • Perform state-of-the-art clinical trials emphasizing innovation and mandating meticulous attention to protocol compliance and data quality.
  • Evaluate the impact of therapy by integrating measures of cancer response and patient outcomes.

Latest News

Adding Immune-based Treatments to Standard Glioblastoma Therapy October 11, 2017

This phase 2 trial is testing standard therapy (surgery, radiation, and temozolomide) plus the checkpoint inhibitor pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor

BTTC Newsletters

The Brain Tumor Trials Collaborative newsletter is published throughout the year with valuable information, accomplishments, and other updates.

Published BTTC Articles and Presentations